ProStar Holdings Inc. Announces Closing of $1 Million Private Placement

ProStar Holdings Inc. ("ProStar" or the "Company") (TSXV: MAPS) (FSE: 5D00) a world leader in Precision Mapping Solutions™, is pleased to announce that the Company has received an order and agreed with a sole subscriber to complete a non-brokered private placement of $1,001,000 through the issuance of 1,430,000 units, at a price of $0.70 per unit to a European Investment Group. The Company intends to use the net proceeds of the Private Placement to expand its global sales network, add additional sales and marketing resources, and for working capital.

Each Unit consists of one common share of the Company (each, a " Share ") and one-half of one non-transferable common share purchase warrant (each whole warrant, a " Warrant "). Each Warrant will entitle the holder to purchase one additional Share at an exercise price of $1.00 per Share for a period of 24 months from the date of issue.

All securities issued in connection with the Offering are subject to a four-month hold period under applicable securities legislation. The Company paid a cash finder's fee in the amount of $70,070 and issued 100,100 finder's warrants, with each finder's warrant exercisable into a common share of the Company at a price of $0.70 for 24 months.

What You Should Know About ProStar (TSXV: MAPS)(FSE: 5D00)

ProStar is a world leader in Precision Mapping Solutions™. ProStar's flagship product, PointMan, is natively cloud and mobile, and offered as a SaaS recurring revenue model. ProStar's solutions are adopted by some of the largest entities in North America , including Fortune 500 construction firms, the largest subsurface utilities engineering (SUE) firms, and government agencies.

ProStar has strategic partnerships with the leading GPS/GNSS and cable and pipe locator manufactures as well as their dealer networks, including Trimble®, Vivax-Metrotech, Radiodetection®, and Subsite® Electronics.

The company has made a significant investment in creating a vast intellectual property portfolio that includes 19 issued patents in the United States and Canada , with several more pending. The patents protect the methods required to digitally capture, record, and display the precise location of buried utilities and pipelines.

ProStar's Executive management team has extensive experience in both early stage and Fortune 500 companies, TSX and TSX.V listed enterprises, and in geospatial, cloud and mobile technologies. ProStar's leadership team includes Vasa Dasan, former CTO of Sun Microsystems, Carl Lashua , previous Chief Information Officer of HSBC Canada and Europe , and Matthew Breman prior Executive for Disneyworld Resorts.

For more information about ProStar, please visit: www.prostarcorp.com .

For further information, please contact:

Alex Moore
Investor Relations Support
investorrelations@prostarcorp.com
970-242-4024

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE ProStar Corp

View original content to download multimedia: https://www.newswire.ca/en/releases/archive/March2021/10/c5502.html

News Provided by Canada Newswire via QuoteMedia

ProStar™ GeoCorp TSXV:MAPS Emerging Tech Investing

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

ProStar Holdings Inc. Announces Closing of $1 Million Private Placement

Latest News

Latest Press Releases

Related News

TOP STOCKS